摘要
色素上皮衍生因子(PEDF)是属于丝氨酸蛋白酶抑制剂、丝氨酸蛋白酶抑制剂超家族的糖蛋白。 它首先被鉴定为人视网膜色素上皮细胞分泌的神经元分化因子,然后被发现是哺乳动物眼中最有效的病理性血管生成抑制剂。 最近,PEDF不仅用于抑制血管壁细胞、T细胞和巨噬细胞和脂肪细胞中的氧化应激和炎症反应,而且还能发挥抗血栓和抗纤维化的特性,从而保护各种心脏代谢疾病和相关并发症的发展和进展。 此外,累积证据表明,循环PEDF水平可能是这些破坏性疾病严重程度和预后的生物标志物。 内脏肥胖和胰岛素抵抗的受试者数量在增加,代谢综合征及其相关并发症,如糖尿病、非酒精性脂肪肝疾病/非酒精性脂肪性肝炎和动脉粥样硬化性心血管疾病是越来越多的健康挑战。 因此,在本研究中,我们回顾了PEDF在肥胖和代谢障碍、心血管疾病、糖尿病眼和肾脏并发症、肝病和生殖系统疾病中的病理生理作用,并讨论了调节PEDF在预防这些心脏代谢障碍中的表达和作用的潜在临床实用性。 我们还提到PEDF的临床价值作为心脏代谢并发症的生物标志物。
关键词: 心血管疾病,炎症,代谢紊乱,氧化应激,PEDF,视网膜病变,糖尿病肾病。
Current Medicinal Chemistry
Title:Pigment Epithelium-Derived Factor: A Novel Therapeutic Target for Cardiometabolic Diseases and Related Complications
Volume: 25 Issue: 13
关键词: 心血管疾病,炎症,代谢紊乱,氧化应激,PEDF,视网膜病变,糖尿病肾病。
摘要: Pigment epithelium-derived factor (PEDF) is a glycoprotein that belongs to the superfamily of serine protease inhibitors, serpins. It was first identified as a neuronal differentiating factor secreted by human retinal pigment epithelial cells, and then found to be the most potent inhibitor of pathological angiogenesis in mammalian eyes. Recently, PEDF has been shown not only to suppress oxidative stress and inflammatory reactions in vascular wall cells, T cells and macrophages, and adipocytes, but also to exert antithrombotic and anti-fibrotic properties, thereby protecting against the development and progression of various cardiometabolic diseases and related complications. Furthermore, accumulating evidence has suggested that circulating PEDF levels may be a biomarker of severity and prognosis of these devastating disorders. Number of subjects with visceral obesity and insulin resistance is increasing, and the metabolic syndrome and its related complications, such as diabetes, nonalcoholic fatty liver disease/non-alcoholic steatohepatits, and atherosclerotic cardiovascular disease are a growing health challenge. Therefore, in this study, we review the pathophysiological role of PEDF in obesity and metabolic disorders, cardiovascular disease, diabetic eye and kidney complications, liver diseases, and reproductive system disorders, and discuss the potential clinical utility of modulating the expression and actions of PEDF for preventing these cardiometabolic disorders. We also refer to the clinical value of PEDF as a biomarker in cardiometabolic complications.
Export Options
About this article
Cite this article as:
Pigment Epithelium-Derived Factor: A Novel Therapeutic Target for Cardiometabolic Diseases and Related Complications, Current Medicinal Chemistry 2018; 25 (13) . https://dx.doi.org/10.2174/0929867324666170608103140
DOI https://dx.doi.org/10.2174/0929867324666170608103140 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
<i>Angelica archangelica</i> and <i>Ginkgo biloba</i> Extracts Recover Functional Blood
Hemoglobin Derivatives in Rabbits Exposed to High Altitude
Current Pharmaceutical Biotechnology The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development
Current Drug Metabolism PDE4D Gene in the STRK1 Region on 5q12: Susceptibility Gene for Ischemic Stroke
Current Medicinal Chemistry Diabetes and Antioxidants: Myth or Reality?
Current Vascular Pharmacology Obesity in China: What are the Causes?
Current Pharmaceutical Design The Role of AGEs and AGE Inhibitors in Diabetic Cardiovascular Disease
Current Drug Targets Current Trend and Pro-survival Approaches for Augmenting Stem Cell Viability
Current Pharmaceutical Biotechnology Protective Effects of Diuretics Against the Development of Cardiovascular Disease in Patients with Chronic Kidney Disease: A Systematic Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Renin-Angiotensin-Aldosterone System Antagonists and the Prevention of Type 2 Diabetes Mellitus
Current Pharmaceutical Design Aldose Reductase / Polyol Inhibitors for Diabetic Retinopathy
Current Pharmaceutical Biotechnology Is there any Additional Prognostic Value of Central Blood Pressure Wave Forms Beyond Peripheral Blood Pressure?
Current Pharmaceutical Design Data Mining of Differentially Expressed Genes in Ovarian Epithelial Carcinoma: Implications in Precise Medicine
Current Topics in Medicinal Chemistry Phytochemicals as Prototypes for Pharmaceutical Leads Towards Drug Development Against Diabetic Cardiomyopathy
Current Pharmaceutical Design Glycoxidation of Low Density Lipoprotein in Impaired Glucose Tolerance: Implications for the Pathogenesis of Diabetic Vascular Disease
Vascular Disease Prevention (Discontinued) Rhein Derivatives, A Promising Pivot?
Mini-Reviews in Medicinal Chemistry The Role of Organic Transporters in Pharmacokinetics and Nephrotoxicity of Newer Antiviral Therapies for HIV and Hepatitis C
Current Drug Metabolism Sodium Glucose Cotransporter-2 Inhibitor Treatment and the Risk of Diabetic Ketoacidosis in Denmark: A Retrospective Cohort Study of Five Years of Use
Current Drug Safety Recent Developments in Patents Targeting Toll-Like Receptor Genes
Recent Patents on DNA & Gene Sequences Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): A Relationship with Implications for Vascular Risk?
Current Vascular Pharmacology Bacteriophage - A Common Divergent Therapeutic Approach for Alzheimer's Disease and Type II Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets